On Monday, Shares of Annaly Capital Management, Inc. (NYSE:NLY), gained 0.31% to $9.81.
Annaly Capital Management, declared that its Board of Directors has designated Kevin Keyes as its Chief Executive Officer. Mr. Keyes will also retain the title of President. Wellington Denahan, Annaly’s co-founder, Chairman and Chief Executive Officer, will remain Chairman of the Board of Directors and will also serve as Executive Chairman of the Company focusing on planned and capital allocation decisions.
Annaly Capital Management, Inc. owns a portfolio of real estate related investments in the United States. The company invests in various types of agency mortgage-backed securities and related derivatives to hedge these investments; acquires, finances, and manages commercial mortgage loans and other commercial real estate debt, commercial mortgage-backed securities, and other commercial real estate-related assets; and operates as a broker-dealer.
Shares of JetBlue Airways Corporation (NASDAQ:JBLU), declined -0.26% to $22.88, during its last trading session, hitting its highest level.
JetBlue Airways Corporation, declared that flights on its recently declared new route between Fort Lauderdale-Hollywood International Airport (FLL) and Providenciales International Airport (PLS) in Turks and Caicos are now on sale. The year-round, daily service starts November 19, 2015. JetBlue is offering an introductory fare of only $99 each way (a) between Fort Lauderdale-Hollywood and Turks and Caicos.
The new route demonstrates JetBlue’s commitment to expansion in the Caribbean, where it is already the largest carrier from the U.S. The flights are also part of JetBlue’s ongoing growth at its focus city in Fort Lauderdale-Hollywood, Fla., where it now offers flights to more than 40 destinations. Eight new destinations, counting Turks and Caicos, have been declared just this year.
JetBlue Airways Corporation, a passenger carrier company, provides air transportation services. As of December 31, 2014, the company operated a fleet of 13 Airbus A321 aircrafts, 130 Airbus A320 aircrafts, and 60 EMBRAER 190 aircrafts.
Finally, Neurocrine Biosciences Inc. (NASDAQ:NBIX), ended its last trade with -1.96% loss, and closed at $52.46, hitting its highest level.
Neurocrine Biosciences, declared that it has suspended two planned clinical studies of the Company’s CRF antagonist NBI-77860.
The two clinical studies that were halted comprise a single dose study in adolescent females with classic congenital adrenal hyperplasia and a multiple dose study in adults with classic congenital adrenal hyperplasia. The Company had not enrolled any subjects in either study and accordingly, there have been no adverse events stated.
The Company has also been informed by the FDA that the NBI-77860 clinical development program would be placed on partial clinical hold.
Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company’s products in clinical development stage comprise elagolix, which is in Phase III study for endometriosis; elagolix that is in Phase IIb study for uterine fibroids.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
